Background: In chronic lymphocytic leukemia (CLL) disease onset and progression are influenced by the behavior of specific CD4 T cell subsets, such as T regulatory cells (Tregs). Here, we focused on the phenotypic and functional characterization of Tregs in CLL patients to improve our understanding of the putative mechanism by which these cells combine immunosuppressive and effector-like properties.
Methods: Peripheral blood mononuclear cells were isolated from newly diagnosed CLL patients (n = 25) and healthy volunteers (n = 25). The phenotypic and functional characterization of Tregs and their subsets was assessed by flow cytometry. In vitro analysis of TH1, TH2, TH17 and Tregs cytokines was evaluated by IFN-γ, IL-4, IL-17A and IL-10 secretion assays. The transcriptional profiling of 84 genes panel was evaluated by RT Profiler PCR Array. Statistical analysis was carried out using exact non parametric Mann-Whitney U test.
Results: In all CLL samples, we found a significant increase in the frequency of IL-10-secreting Tregs and Tregs subsets, a significant rise of TH2 IL-4 and TH17 IL-17A cells, and a higher percentage of IFN-γ/IL-10 and IL-4/IL-10 double-releasing CD4 T cells. In addition, we also observed the up-regulation of innate immunity genes and the down-regulation of adaptive immunity ones.
Conclusions: Our data show that Tregs switch towards an effector-like phenotype in CLL patients. This multifaceted behavior is accompanied by an altered cytokine profiling and transcriptional program of immune genes, leading to a dysfunction in immune response in the peripheral blood environment of CLL patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6011245 | PMC |
http://dx.doi.org/10.1186/s12967-018-1545-0 | DOI Listing |
Nat Commun
January 2025
Department of Machine Learning, Moffitt Cancer Center, Tampa, FL, USA.
AI decision support systems can assist clinicians in planning adaptive treatment strategies that can dynamically react to individuals' cancer progression for effective personalized care. However, AI's imperfections can lead to suboptimal therapeutics if clinicians over or under rely on AI. To investigate such collaborative decision-making process, we conducted a Human-AI interaction study on response-adaptive radiotherapy for non-small cell lung cancer and hepatocellular carcinoma.
View Article and Find Full Text PDFAJNR Am J Neuroradiol
January 2025
Department of Neurology, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium.
Purpose: Posterior fossa ring-enhancing lesions (PFREL) in the adult immunocompetent hosts pose a diagnostic challenge. We aimed to evaluate the spectrum of PFREL etiologies and propose a diagnostic algorithm.
Methods: This study involved a retrospective analysis of PFREL cases from our institution (January 2023 to April 2024) and a systematic literature review conducted using Embase and PubMed databases following the PRISMA 2020 guidelines.
Leuk Lymphoma
January 2025
School of Clinical Sciences at Monash Health, Lymphoma Research Group, Monash University, Clayton, Australia.
Over the past two decades, there has been a continuous improvement in outcome for patients with indolent lymphoma (iNHL) resulting in a gradual accumulation of survivors. While life expectancy in the current era approaches that of the lymphoma-free population, patients continue to experience lifelong complications of the disease and its treatment affecting general health, emotional, psychological and social wellbeing, relationships, employment, finances, and fitness. Contemporary care models while suited to the management of lymphoma are often lacking when it comes to identification and management of these additional needs.
View Article and Find Full Text PDFAsian Pac J Cancer Prev
January 2025
Principal Scientific Officer & Molecular Advisor, Rajiv Gandhi Cancer Institute & Research Centre, New Delhi, India.
Chronic lymphocytic leukemia (CLL) is a less common hematological malignancy in Indian people. It accounts for less than 5% of all leukemias. Information on genomic alteration in CLL is limited immunoglobulin heavy-chain variable region (IGHV) mutational status is considered the most reliable prognostic marker.
View Article and Find Full Text PDFCancer Med
February 2025
Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Chiba, Japan.
Background: Due to its rarity, there are very limited data available on the cause of death (COD) and its association with comorbidities in Japanese chronic lymphocytic leukemia (CLL) patients.
Methods: To investigate the prevalence of comorbidities and their impact on cause-specific mortality, we retrospectively reviewed 121 Japanese patients with CLL.
Results: The median age was 69 years, with 47.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!